- Home
- BIIB vs BBDO Comparison
BIIB vs BBDO Comparison
Compare BIIB & BBDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- BBDO
- Stock Information
- Founded
- BIIB 1978
- BBDO 1943
- Country
- BIIB United States
- BBDO Brazil
- Employees
- BIIB N/A
- BBDO N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- BBDO Major Banks
- Sector
- BIIB Health Care
- BBDO Finance
- Exchange
- BIIB Nasdaq
- BBDO Nasdaq
- Market Cap
- BIIB 18.8B
- BBDO 26.1B
- IPO Year
- BIIB 1991
- BBDO N/A
- Fundamental
- Price
- BIIB $130.43
- BBDO $2.83
- Analyst Decision
- BIIB Buy
- BBDO Strong Buy
- Analyst Count
- BIIB 27
- BBDO 4
- Target Price
- BIIB $188.17
- BBDO $2.55
- AVG Volume (30 Days)
- BIIB 1.3M
- BBDO 49.1K
- Earning Date
- BIIB 07-31-2025
- BBDO 08-04-2025
- Dividend Yield
- BIIB N/A
- BBDO 4.51%
- EPS Growth
- BIIB 26.39
- BBDO 44.93
- EPS
- BIIB 10.12
- BBDO 0.31
- Revenue
- BIIB $9,816,400,000.00
- BBDO $14,585,863,742.00
- Revenue This Year
- BIIB N/A
- BBDO $68.75
- Revenue Next Year
- BIIB N/A
- BBDO $8.99
- P/E Ratio
- BIIB $12.85
- BBDO $9.31
- Revenue Growth
- BIIB 1.59
- BBDO 23.20
- 52 Week Low
- BIIB $110.04
- BBDO $1.71
- 52 Week High
- BIIB $238.00
- BBDO $2.85
- Technical
- Relative Strength Index (RSI)
- BIIB 44.72
- BBDO 60.72
- Support Level
- BIIB $123.90
- BBDO $2.53
- Resistance Level
- BIIB $129.27
- BBDO $2.69
- Average True Range (ATR)
- BIIB 2.85
- BBDO 0.10
- MACD
- BIIB -0.66
- BBDO -0.01
- Stochastic Oscillator
- BIIB 19.77
- BBDO 86.24
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About BBDO Banco Bradesco Sa (each representing one Common Share)
Banco Bradesco is Brazil's second-largest private bank, with about 15% of deposits, and the largest insurance provider in Brazil, with roughly 20%-25% market share. The bank is majority controlled by the Bradesco foundation—a private nonprofit institution focused on education. Banking provides roughly 70% of profits, while the insurance segment contributes the remaining 30%. The bank is also a major asset manager with high-single-digit market share. In 2016, Bradesco acquired the Brazilian operations of HSBC.